InnovatioNews published another profile about Sharklet and the company’s expected growth. Be sure to scroll to the bottom of the article to see an interview with our CEO, Mark Spiecker, where he talks about the company at the Rocky Mountain Life Science Investor & Partnering Conference.
“So much of our technology uses chemicals or heavy metals to prevent bacterial growth,” says Mark Spiecker, who joined the company in 2008 and took over as CEO in 2010 when it moved to the Bioscience Park Center incubator.
“We don’t need that. With our surface, if the bacteria can’t attach, they don’t have the chance to grow. We come at that problem from an entirely new angle.”
Regional manufacturing publication Company Week dropped by Sharklet to do a profile of the company and our upcoming products.
“There’s a significant market for iPhone cases,” explains Sharklet CEO Mark Spiecker. “Everybody knows what an iPhone case is, and when I walk into a meeting and show him or her our technology it’s a very tangible thing,” he says. He shows the data on how the case repels bacteria based on Sharklet’s patented technologies. Hence a company focused on medical devices and planning to debut its first products this year is starting out with an iPhone case under $30.
Microsoft’s Work blog wrote a profile about biomimicry and Sharklet.
Today, businesses are looking at how nature works to find solutions for human problems. This emergent field is called “biomimicry,” from the Greek bios (life) and mimesis (imitation). In business, biomimicry means innovations inspired by nature, and so far, the greatest business advances in biomimicry have been design oriented. However, Mother Nature is also the Master Organizer of things. Perhaps it’s time to consider her opinion on the way we organize our lives and businesses.
Platelet adhesion and activation are key events in thrombus or clot formation on blood-contacting biomaterials. Thus understanding the complex interactions between biomaterial surface properties and platelets is important for developing vascular access devices that limit thromboembolic events. Medical-grade poly(urethanes) are frequently used in blood-contacting medical devices due to their desirable mechanical properties and high level of hemocompatibility. Moreover, it has been shown that sub-platelet-sized micropatterns reduce platelet adhesion. Based on this evidence, we hypothesized that bio-inspired, antifouling Sharklet™ (SK) microtopographies replicated in biomedical thermoplastic poly(urethane) (TPU) reduce both platelet adhesion and activation compared to smooth (SM) controls.
Ventilator-associated pneumonia (VAP) is a leading hospital acquired infection in intensive care units despite improved patient care practices and advancements in endotracheal tube (ETT) designs. The ETT provides a conduit for bacterial access to the lower respiratory tract and a substratum for biofilm formation, both of which lead to VAP. A novel microscopic ordered surface topography, the Sharklet micro-pattern, has been shown to decrease surface attachment of numerous microorganisms, and may provide an alternative strategy for VAP prevention if included on the surface of an ETT. To evaluate the feasibility of this micro-pattern for this application, the microbial range of performance was investigated in addition to biofilm studies with and without a mucin-rich medium to simulate the tracheal environment in vitro.
FOR IMMEDIATE RELEASE: June 23, 2014
AURORA, COLO. – Sharklet Technologies’ has joined an esteemed group of companies recognized for fueling Colorado’s economic growth – the Colorado Companies to Watch Class of 2014. The program honors privately-held, growth-focused companies that are leading the state in innovation and job creation.